Skip to main content
Log in

Factors that Motivate Healthcare Professionals to Report Adverse Drug Events: A Systematic Review

  • Systematic Review
  • Published:
Pharmaceutical Medicine Aims and scope Submit manuscript

Abstract

Introduction

The underreporting of adverse drug events (ADEs) is an important issue that affects the evaluation of the risk/benefit profile of drugs, with the potential for major impact on public health, such as undermining market regulation of drugs and reducing patient safety.

Objectives

The objective of this systematic review was to identify and categorize the factors that motivate ADE reporting by healthcare professionals.

Methods

A systematic review was conducted, based on the PRISMA guidelines, in the PubMed, Scopus, LILACS and SciELO databases, for studies published up to 30 November 2015. A search strategy was designed to identify published studies that evaluated factors that motivate professionals to report adverse events. Factors that were identified as influencing ADE reporting were subsequently categorized by the authors, to reveal common themes that might be used to improve ADE reporting rates.

Results

There were 410 potentially relevant studies identified, of which 133 were duplicates and 234 did not meet the inclusion criteria at initial screening. After reading in full, a further 15 articles were eliminated and 28 articles were included in the systematic review. It was observed that the majority of studies mainly contemplated pharmacists (n = 16) and physicians (n = 16). The seven major categories that motivate ADE reporting by health professionals are: knowledge of the ADE, incentives, notification methods, educational intervention, risk management, educational materials, and professional responsibility.

Conclusions

Factors that motivate healthcare professional to report ADEs can be classified into seven common themes. It is likely that multiple categories will need to be addressed as part of ongoing continuing education programs to increase motivation for ADE reporting by healthcare professionals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Souza TT, Godoy RR, Rotta I, Pontarolo R, Fernandez-Llimos F, Correr CJ. Morbidade e mortalidade relacionadas a medicamentos no Brasil: revisão sistemática de estudos observacionais. Rev Ciênc Farm Básica Apl. 2014;35(4):519–32.

    Google Scholar 

  2. Camargo AL, Ferreira MBC, Heineck I. Adverse Drug reactions: a cohort study in internal medicine units at a university hospital. Eur J Clin Pharmacol. 2006;62(2):143–9.

    Article  PubMed  Google Scholar 

  3. Pirmohamed M, James S, Meakin S, Verde C, Scott AK, Walley TJ, Farrar K, Parque BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15–9.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277(4):301–6.

    Article  CAS  PubMed  Google Scholar 

  5. Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013;36(2):75–81.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Baldoni AO, Pereira LRL. O impacto do envelhecimento populacional brasileiro para o sistema de saúde sob a óptica da farmacoepidemiologia: uma revisão narrativa. Rev Ciênc Farm Básica e Apl. 2011;32(3):313–21.

    Google Scholar 

  7. Abjaude SAR, Zanetti ACB, Marques LAM, Rascado RR. Omission in reporting: result of ignorance in pharmacovigilance. Revista da Universidade do Vale do Rio Verde Três Corações. 2013;10(1):267–76.

    Article  Google Scholar 

  8. Gavaza P, Brown CM, Lawson KA, Rascati KL, Wilson JP, Steinhardt M. Influence of attitudes on pharmacist’ intention to report serious adverse drug events to the Food and Drug Administration. Br J Clin Pharmacol. 2011;72(1):143–52.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31.

    Article  CAS  PubMed  Google Scholar 

  10. Ribeiro-Vaz I, Herdeiro MT, Polónia J, Figueiras A. Strategies to increase the sensitivity of pharmacovigilance in Portugal. Rev Saúde Pública. 2011;45(1):129–35.

    Article  PubMed  Google Scholar 

  11. Primo LP, Capucho HC. Educational interventions for stimulating voluntary reporting in a university hospital sentinel. R Bras Farm Hosp Serv Saúde São Paulo. 2011;2(2):26–30.

    Google Scholar 

  12. Gavaza P, Brown CM, Khoza S. Texas pharmacists’ opinions on reporting serious adverse drug events to the Food and Drug Administration: a qualitative study. Pharm World Sci. 2010;32:651–7.

    Article  PubMed  Google Scholar 

  13. Su C, Ji H, Su Y. Hospital pharmacists’ knowledge and opinions regarding adverse drug reaction reporting in Northern China. Pharmacoepidemiol Drug Saf. 2010;19(3):217–22.

    Article  PubMed  Google Scholar 

  14. Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol. 2009;151(4):264–70.

    Google Scholar 

  15. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Commun Health. 1998;52:377–84.

    Article  CAS  Google Scholar 

  16. Vincent C, Stanhope N, Crowley-Murphy M. Reasons for not reporting adverse incidents: an empirical study. J Eval Clin Pract. 1999;5(1):13–21.

    Article  CAS  PubMed  Google Scholar 

  17. Herdeiro MT, Polonia J, Gestal-Otero JJ, Figueiras A. Factors that influence spontaneous reporting of adverse drug reactions: a model centralized in the medical professional. J Eval Clin Pract. 2004;10(4):483–9.

    Article  PubMed  Google Scholar 

  18. Smith DS, Haig K. Reduction of adverse drug events and medication errors in a community hospital setting. Nurs Clin N Am. 2005;40(1):25–32.

    Article  Google Scholar 

  19. Chaikoolvatana A, Chanakit T, Juengrakpong A. The evaluation of a recurrent adverse drug reaction prevention program in the North-East region of Thailand. J Med Assoc Thai. 2006;89(5):699–705.

    CAS  PubMed  Google Scholar 

  20. Olmsted SS, Grabenstein JD, Jain AK, Lurie N. Patient experience with, and use of, an electronic monitoring system to assess vaccination responses. Health Expect. 2006;9(2):110–7.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Nichols V, Thériault-Duhé I, Touzin J, Delisle JF, Lebel D, Bussières JF, Bailey B, Collin J. Risk perception and reasons for noncompliance in pharmacovigilance: a qualitative study conducted in Canada. Drug Saf. 2009;32(7):579–90.

    Article  PubMed  Google Scholar 

  22. Passier A, ten Napel M, van Grootheest K, van Puijenbroek E. Reporting of adverse drug reactions by general practitioners: a questionnaire-based study in the Netherlands. Drug Saf. 2009;32(10):851–8.

    Article  PubMed  Google Scholar 

  23. Chopra D, Wardhan N, Rehan HS. Knowledge, attitude and practices associated with adverse drug reaction reporting amongst doctors in a teaching hospital. Int J Risk Saf Med. 2011;23(4):227–32.

    PubMed  Google Scholar 

  24. Arnott J, Hesselgreaves H, Nunn AJ, Peak M, Pirmohamed M, Smyth RL, Mark A, Turner MA, Young B. What can we learn from parents about enhancing participation in pharmacovigilance? Brit J Clin Pharmacol. 2012;75(4):1109–17.

    Article  Google Scholar 

  25. Gavaza P, Bui B. Pharmacy students’ attitudes toward reporting serious adverse drug events. Am J Pharm Educ. 2012;76(10):194.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Baysari MT, Westbrook JL, Egan B, Day RO. Identification of strategies to reduce computerized alerts in an electronic prescribing system using a Delphi approach. Stud Health Technol Inform. 2013;192:8–12.

    PubMed  Google Scholar 

  27. Stewart D, MacLure K, Paudyal V, Hughes C, Courtenay M, McLay J. Non-medical prescribers and pharmacovigilance: participation, competence and future needs. Int J Clin Pharm. 2013;35(2):268–74.

    Article  PubMed  Google Scholar 

  28. Yip J, Radford DR, Brown D. Summary of: How do UK dentists deal with adverse drug reaction reporting? Brit Dental J. 2013;214(8):412–4.

    Article  Google Scholar 

  29. Abubakar AR, Simbak NB, Haque M. Pharmacovigilance study: awareness among medical students of a new medical school of Malaysia. Int J Pharm Res. 2015;7(1):83–8.

    Google Scholar 

  30. Matos C, Van Hunsel F, Joaquim J. Are consumers ready to take part in the Pharmacovigilance System? A Portuguese preliminary study concerning ADR reporting. Eur J Clin Plarmacol. 2015;71:883–90.

    Article  Google Scholar 

  31. Mcgettigan P, Golden J, Conroy RM, Arthur N, Felly J. Reporting of adverse drug reactions by hospital doctors and the response to intervention. Brit J Clin Pharmacol. 1997;44:98–100.

    Article  CAS  Google Scholar 

  32. Cosentino M, Leoni O, Oria C, Michielotto D, Massimo E, Lecchini S, Frigo G. Hospital-based survey of doctor’s attitudes to adverse drug reactions and perception of drug-related risk for adverse reaction occurrence. Pharmacoepidemiol Drug Saf. 1999;8:S27–35.

    Article  PubMed  Google Scholar 

  33. Castel JM, Figueras A, Pedrós C, Laporte JR, Capellà D. Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Saf. 2003;26(14):1049–55.

    Article  PubMed  Google Scholar 

  34. Bäckström M, Mjörndal T. A small economic inducement to stimulate increased reporting of adverse drug reactions—a way of dealing with an old problem? Eur J Clin Pharmacol. 2006;62:381–5.

    Article  PubMed  Google Scholar 

  35. Wallerstedt SM, Brunlöf G, Johansson ML, Tukukino C, Ny L. Reporting of adverse drug reactions may be influenced by feedback to the reporting doctor. Eur J Clin Pharmacol. 2007;63(5):505–8.

    Article  PubMed  Google Scholar 

  36. Granas AG, Buajordet M, Stenberg-Nilsen H, Harg P, Horn AM. Pharmacists’ attitudes towards the reporting of suspected adverse drug reactions in Norway. Pharmacoepidemiol Drug Saf. 2007;16:429–34.

    Article  PubMed  Google Scholar 

  37. Irujo M, Bietia G, Bes-Rastrollo M, Figueiras A, Hernandez-Díaz S, Lasheras B. Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region. Drug Saf. 2007;30(11):1073–82.

    Article  PubMed  Google Scholar 

  38. Cornelissen L, Puijenbroek E, Grootheest K. Expectations of general practitioners and specialist doctors regarding the feedback received after reporting an adverse drug reaction. Pharmacoepidemiol Drug Saf. 2008;17:76–81.

    Article  PubMed  Google Scholar 

  39. Wu JH, Shen WS, Lin LM, Greenes RA, Bates DW. Testing the technology acceptance model for evaluating healthcare professionals’ intention to use an adverse event reporting system. Int J Qual Health Care. 2008;20(2):123–9.

    Article  PubMed  Google Scholar 

  40. Ekman E, Bäckström M. Attitudes among hospital physicians to the reporting of adverse drug reactions in Sweden. Eur J Clin Pharmacol. 2009;65:43–6.

    Article  PubMed  Google Scholar 

  41. Polimeni G, Russo A, Catania MA, Aiello A, Oteri A, Trifirò G, Calapai G, Sautebin L, Iacobelli M, Caputi AP. Drug safety information through the internet the experience of an Italian website. Drug Saf. 2009;32(3):245–53.

    Article  PubMed  Google Scholar 

  42. Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. BMC Clin Pharmacol. 2009;9(14):1–8.

    Google Scholar 

  43. Vessal G, Mardani Z, Mollai M. Knowledge, attitudes, and perceptions of pharmacists to adverse drug reaction reporting in Iran. Pharm World Sci. 2009;31(2):183–7.

    Article  PubMed  Google Scholar 

  44. Weingart SN, Massagli M, Cyrulik A, Isaac T, Morway L, Sands DZ, Weissman JS. Assessing the value of electronic prescribing in ambulatory care: a focus group study. Int J Med Inform. 2009;78(9):571–8.

    Article  PubMed  Google Scholar 

  45. Kozamernik B. Spontaneous adverse drug reaction reporting: attitudes and practice of health care professionals and distributors in South East European region. Farm Vestn. 2010;61:271–81.

    Google Scholar 

  46. Ting KN, Stratton-Powell DM, Anderson C. Community pharmacists’ views on adverse drug reactions reporting in Malaysia: a pilot study. Pharm World Sci. 2010;32(3):339–42.

    Article  PubMed  Google Scholar 

  47. Tobaiqy M, Stewart D, Helms PJ, Bond CM, Lee AJ, McLay J. Views of parents and pharmacists following participation in a paediatric pharmacovigilance study. Pharm World Sci. 2010;32(3):334–8.

    Article  PubMed  Google Scholar 

  48. Gavaza P, Brown CM, Lawson KA, Rascati KL, Wilson JP, Steinhardt M. Examination of pharmacists’ intention to report serious adverse drug events (ADEs) to the FDA using the theory of planned behavior. Res Soc Admin Pharm. 2011;7(4):369–82.

    Article  Google Scholar 

  49. Gavaza P, Brown CM, Lawson KA, Rascati KL, Steinhardt M, Wilson JP. Effect of social influences on pharmacists’ intention to report adverse drug events. J Am Pharm Assoc. 2012;52(5):622–9.

    Article  Google Scholar 

  50. Gavaza P, Brown CM, Lawson KA, Rascati KL, Steinhardt M, Wilson JP. Pharmacist reporting of serious adverse drug events to the Food and Drug Administration. J Am Pharm Assoc. 2012;52(5):109–12.

    Article  Google Scholar 

  51. Oosterhuis I, Hunsef FPAM, Puijenbroek EP. Expectations for feedback in adverse drug reporting by healthcare professionals in the Netherlands. Drug Saf. 2012;35(3):221–32.

    PubMed  Google Scholar 

  52. Santosh KC, Tragulpiankit P, Gorsanan S, Edwards IR. Attitudes among healthcare professionals to the reporting of adverse drug reactions in Nepal. BMC Pharmacol Toxicol. 2013;14(16):1–7.

    Google Scholar 

  53. Sanghavi DR, Dhande PP, Pandit VA. Perception of pharmacovigilance among doctors in a tertiary care hospital: influence of an interventional lecture. Int J Risk Saf Med. 2013;25(4):197–204.

    PubMed  Google Scholar 

  54. Elkalmi RM, Hassali MA, Ibrahim MI, Jamshed SQ, Al-Lela OQ. Community pharmacists’ attitudes, perceptions, and barriers toward adverse drug reaction reporting in Malaysia: a quantitative insight. J Patient Saf. 2014;10(2):81–7.

    Article  PubMed  Google Scholar 

  55. Al-Arifi MN, Mayet AY, Wajid S, Al-Saadi M, Babelghaith AEMISD, Al Ayoubi FZ. Knowledge, attitude and perception of physicians towards adverse drug reaction reporting at King Khalid University Hospital, Riyadh, Saudi Arabia. Trop J Pharm Res. 2015;14(5):907–11.

    Article  Google Scholar 

  56. Inman WHW. Assessment drug safety problems. In: Gent M, Shigmatsu I, editors. Epidemiological issues in reported drug-induced illnesses. Honolulu: McMaster University Library Press; 1976. p. 17–24.

    Google Scholar 

  57. Varallo FR, Guimarães SOP, Abjaude SAR, Mastroianni PC. Causes for the underreporting of adverse drug events by health professionals: a systematic review. Rev Esc Enferm USP. 2014;48(4):739–47.

    Article  PubMed  Google Scholar 

  58. Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Strategies to improve adverse drug reaction reporting: a critical and systematic review. Drug Saf. 2013;36(5):317–28.

    Article  CAS  PubMed  Google Scholar 

  59. Pagotto C, Varallo FR, Mastroianni PC. Impact of educational interventions on adverse drug events reporting. Int J Technol Assess Health Care. 2013;29(4):410–41.

    Article  PubMed  Google Scholar 

  60. Hopf YM, Bond C, Francis J, Haughney J, Helms PJ. Views of healthcare professionals to linkage of routinely collected healthcare data: a systematic literature review. J Am Med Inform Assoc. 2014;21(e1):e6–10.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Marilia Silveira de Almeida Campos for statistical cooperation and revision of the text.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Leonardo Régis Leira Pereira.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this systematic review.

Conflict of interest

Samir Antonio Rodrigues Abjaude, Stephania Furlanetto Mieli, Zídia Rocha Magalhães and Leonardo Régis Leira Pereira have no conflicts of interest that are directly relevant to the content of this systematic review.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 40 kb)

Supplementary material 2 (PDF 91 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abjaude, S.A.R., Mieli, S.F., Magalhães, Z.R. et al. Factors that Motivate Healthcare Professionals to Report Adverse Drug Events: A Systematic Review. Pharm Med 31, 13–20 (2017). https://doi.org/10.1007/s40290-016-0174-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40290-016-0174-2

Keywords

Navigation